IDEXX LABORATORIES INC /DE Share-based Payment Arrangement, Expense, after Tax
IDEXX LABORATORIES INC /DE (IDXX) reported Share-based Payment Arrangement, Expense, after Tax of $24.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-02-20
- IDEXX LABORATORIES INC /DE share-based payment arrangement, expense, after tax for fiscal 2025 was $24.75M, a 27.23% decline from fiscal 2024.
- IDEXX LABORATORIES INC /DE share-based payment arrangement, expense, after tax for fiscal 2024 was $34.02M, a 16.10% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE share-based payment arrangement, expense, after tax for fiscal 2023 was $40.55M, a 24.42% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE share-based payment arrangement, expense, after tax for fiscal 2022 was $32.59M, a 5857.95% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|
| 2025-12-31 | $24.75M 10-K · filed 2026-02-20 |
| 2024-12-31 | $34.02M 10-K · filed 2026-02-20 |
| 2023-12-31 | $40.55M 10-K · filed 2026-02-20 |
| 2022-12-31 | $32.59M 10-K · filed 2025-02-21 |
| 2021-12-31 | $547.00K 10-K · filed 2024-02-22 |
| 2020-12-31 | -$11.99M 10-K · filed 2023-02-16 |
| 2019-12-31 | $15.28M 10-K · filed 2022-02-16 |
| 2018-12-31 | -$529.00K 10-K · filed 2021-02-12 |
| 2017-12-31 | -$11.04M 10-K · filed 2020-02-14 |
| 2016-12-31 | $13.75M 10-K · filed 2019-02-15 |
| 2015-12-31 | $13.65M 10-K · filed 2018-02-16 |
| 2014-12-31 | $11.99M 10-K · filed 2017-02-17 |
| 2013-12-31 | $10.99M 10-K · filed 2016-02-17 |
| 2012-12-31 | $10.52M 10-K · filed 2015-02-17 |
| 2011-12-31 | $10.25M 10-K · filed 2014-02-18 |
| 2010-12-31 | $8.66M 10-K · filed 2013-02-19 |
| 2009-12-31 | $7.80M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |